SPOTLIGHT: Does the patent cliff drive innovation?

Is generic competition good for the biotech and pharma industries? An article from The San Francisco Chronicle argues that as aging drugs go off patent, companies are forced to push innovation to new heights in an effort to render older drugs obsolete. Article

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.